BioCentury | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

...head of oncology therapeutic area in marketing strategy. Astellas Pharma Inc. (Tokyo:4503) also hired Michael Rafa...
BioCentury | Jan 27, 2017
Clinical News

Tedopi: Ph III Atalante 1 ongoing

...or pemetrexed every 3 weeks. A second IDMC review is expected to occur in 2Q17. Rafa...
...Tedopi in Israel (see BioCentury, June 8, 2015 ). OSE Immunotherapeutics S.A. (Euronext:OSE), Nantes, France Rafa Laboratories Ltd....
...outcomes Status: Phase III ongoing Milestone: Phase III data (year end 2018) Julian Zhu OSE 2101 Tedopi OSE Immunotherapeutics S.A. Rafa Laboratories Ltd....
BioCentury | Feb 1, 2016
Clinical News

Tedopi: Phase III started

...until disease progression or unacceptable toxicity. Patients will receive docetaxel or pemetrexed every 3 weeks. Rafa...
...Orphan Synergy Europe to develop and commercialize Tedopi in Israel (see BioCentury, June 8, 2015). Rafa Laboratories Ltd....
BioCentury | Jun 8, 2015
Company News

OSE Pharma, Rafa deal

...Orphan Synergy Europe granted Rafa exclusive rights to develop and commercialize Tedopi in Israel. Rafa will...
...equally share profits from sales in Israel. OSE declined to provide further financial terms, and Rafa...
...U.S. and Europe. Data are expected in 2018. Orphan Synergy Europe-Pharma S.A. (Euronext:OSE), Paris, France Rafa Laboratories Ltd....
BioCentury | Aug 4, 2014
Company News

Rafarma Pharmaceuticals management update

...Rafarma Pharmaceuticals Inc. (Pink:RAFA), Draper, Utah Business: Infectious, Cancer, Generics Hired: Bruno Horn as president and...
BioCentury | Feb 3, 2014
Company News

Pharmsynthez, Rafarma Pharmaceuticals deal

...deal. Pharmsynthez is an API manufacturer. Pharmsynthez JSC (MICEX:LIFE), St. Petersburg, Russia Rafarma Pharmaceuticals Inc. (Pink:RAFA...
BioCentury | Dec 23, 2013
Financial News

Rafarma Pharmaceuticals completes private placement

...Rafarma Pharmaceuticals Inc. (Pink:RAFA), Draper, Utah Business: Infectious, Cancer, Generics Date completed: 12/12/13 Type: Private placement...
BioCentury | May 14, 2012
Finance

The lure of research

The lure of research The Tel Aviv Stock Exchange is planning to provide analyst research reports for its listed life sciences companies as part of an effort to attract dual-listings for U.S. companies on the...
BioCentury | May 2, 2005
Company News

Sinclair, Forest Laboratories, Kalbe Pharma, Rafa Laboratories Ltd. sales and marketing update

...Sinclair granted Rafa Israeli distribution rights to its Atopiclair non-steroidal cream for atopic dermatitis and allergic...
...Godalming, U.K. Forest Laboratories Inc. (FRX), New York, N.Y. Kalbe Pharma , Bekasi, Indonesia Rafa Laboratories Ltd....
BioCentury | Oct 11, 2004
Company News

Helsinn Healthcare SA, Rafa Ltd. sales and marketing update

...by Helsinn's partner MGI Pharma Inc. (MOGN, Minneapolis, Minn.). Helsinn Healthcare SA , Lugano, Switzerland Rafa...
Items per page:
1 - 10 of 11
BioCentury | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

...head of oncology therapeutic area in marketing strategy. Astellas Pharma Inc. (Tokyo:4503) also hired Michael Rafa...
BioCentury | Jan 27, 2017
Clinical News

Tedopi: Ph III Atalante 1 ongoing

...or pemetrexed every 3 weeks. A second IDMC review is expected to occur in 2Q17. Rafa...
...Tedopi in Israel (see BioCentury, June 8, 2015 ). OSE Immunotherapeutics S.A. (Euronext:OSE), Nantes, France Rafa Laboratories Ltd....
...outcomes Status: Phase III ongoing Milestone: Phase III data (year end 2018) Julian Zhu OSE 2101 Tedopi OSE Immunotherapeutics S.A. Rafa Laboratories Ltd....
BioCentury | Feb 1, 2016
Clinical News

Tedopi: Phase III started

...until disease progression or unacceptable toxicity. Patients will receive docetaxel or pemetrexed every 3 weeks. Rafa...
...Orphan Synergy Europe to develop and commercialize Tedopi in Israel (see BioCentury, June 8, 2015). Rafa Laboratories Ltd....
BioCentury | Jun 8, 2015
Company News

OSE Pharma, Rafa deal

...Orphan Synergy Europe granted Rafa exclusive rights to develop and commercialize Tedopi in Israel. Rafa will...
...equally share profits from sales in Israel. OSE declined to provide further financial terms, and Rafa...
...U.S. and Europe. Data are expected in 2018. Orphan Synergy Europe-Pharma S.A. (Euronext:OSE), Paris, France Rafa Laboratories Ltd....
BioCentury | Aug 4, 2014
Company News

Rafarma Pharmaceuticals management update

...Rafarma Pharmaceuticals Inc. (Pink:RAFA), Draper, Utah Business: Infectious, Cancer, Generics Hired: Bruno Horn as president and...
BioCentury | Feb 3, 2014
Company News

Pharmsynthez, Rafarma Pharmaceuticals deal

...deal. Pharmsynthez is an API manufacturer. Pharmsynthez JSC (MICEX:LIFE), St. Petersburg, Russia Rafarma Pharmaceuticals Inc. (Pink:RAFA...
BioCentury | Dec 23, 2013
Financial News

Rafarma Pharmaceuticals completes private placement

...Rafarma Pharmaceuticals Inc. (Pink:RAFA), Draper, Utah Business: Infectious, Cancer, Generics Date completed: 12/12/13 Type: Private placement...
BioCentury | May 14, 2012
Finance

The lure of research

The lure of research The Tel Aviv Stock Exchange is planning to provide analyst research reports for its listed life sciences companies as part of an effort to attract dual-listings for U.S. companies on the...
BioCentury | May 2, 2005
Company News

Sinclair, Forest Laboratories, Kalbe Pharma, Rafa Laboratories Ltd. sales and marketing update

...Sinclair granted Rafa Israeli distribution rights to its Atopiclair non-steroidal cream for atopic dermatitis and allergic...
...Godalming, U.K. Forest Laboratories Inc. (FRX), New York, N.Y. Kalbe Pharma , Bekasi, Indonesia Rafa Laboratories Ltd....
BioCentury | Oct 11, 2004
Company News

Helsinn Healthcare SA, Rafa Ltd. sales and marketing update

...by Helsinn's partner MGI Pharma Inc. (MOGN, Minneapolis, Minn.). Helsinn Healthcare SA , Lugano, Switzerland Rafa...
Items per page:
1 - 10 of 11